DeepMed Research

Ottawa Hospital Research Institute

🇨🇦Canada

Country: 🇨🇦Canada

Ownership: Private

Established: 2001-01-01

Employees: 5K

Market Cap: -

Website: http://www.ohri.ca

Clinical Trials

4-weekly Versus 12-weekly Administration of Bone-targeted Agents in Patients With Bone Metastases

Phase 4

Completed

Conditions: Breast Cancer
Prostate Cancer
Metastasis

Interventions: Drug: Pamidronate
Drug: Denosumab
Drug: Zoledronate

First Posted Date: 2016-03-29

Last Posted Date: 2020-12-02

Lead Sponsor: Ottawa Hospital Research Institute

Target Recruit Count: 263

Registration Number: NCT02721433

Locations: 🇨🇦
The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada

Crystalloid FLUID Choices for Resuscitation of Hospital Patients

Not Applicable

Completed

Conditions: Fluid Therapy

Interventions: Other: Ringer's Lactate
Other: Normal Saline

First Posted Date: 2016-03-29

Last Posted Date: 2018-10-01

Lead Sponsor: Ottawa Hospital Research Institute

Target Recruit Count: 30000

Registration Number: NCT02721485

Locations: 🇨🇦
Ottawa Hospital Civic Campus, Ottawa, Ontario, Canada
🇨🇦
Hamilton General Hospital, Hamilton, Ontario, Canada
🇨🇦
The Ottawa Hospital General Campus, Ottawa, Ontario, Canada

and more 1 locations

An Integrated Consent Model Study to Compare Two Standard of Care Schedules for Monitoring Cardiac Function in Patients Receiving Trastuzumab for Early Stage Breast Cancer

Phase 4

Completed

Conditions: Breast Cancer

Interventions: Procedure: LVEF 3 month
Procedure: LVEF 4 month

First Posted Date: 2016-03-02

Last Posted Date: 2021-03-03

Lead Sponsor: Ottawa Hospital Research Institute

Target Recruit Count: 200

Registration Number: NCT02696707

Locations: 🇨🇦
The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada
🇨🇦
The Ottawa Hospital, Ottawa, Ontario, Canada

Ig PRx in AECOPD: Pilot Study

Phase 2

Completed

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: Intravenous immunoglobulin (IVIG)
Drug: Normal Saline

First Posted Date: 2016-02-24

Last Posted Date: 2019-11-27

Lead Sponsor: Ottawa Hospital Research Institute

Target Recruit Count: 48

Registration Number: NCT02690038

Locations: 🇨🇦
The Ottawa Hospital, General Campus, Ottawa, Ontario, Canada

Safety Study of Enoxaparin Prophylaxis in Critically Ill Adults With Severe Renal Insufficiency

Conditions: Hemorrhage

First Posted Date: 2016-02-24

Last Posted Date: 2016-02-24

Lead Sponsor: Ottawa Hospital Research Institute

Target Recruit Count: 30

Registration Number: NCT02690090

Locations: 🇨🇦
The Ottawa Hospital, Ottawa, Ontario, Canada

Feasibility of Using an Integrated Consent Model to Compare Two Standard of Care Regimens for the Management of Hypomagnesemia From Anti-Cancer Therapies

Not Applicable

Completed

Conditions: Hypomagnesemia

Interventions: Other: Magnesium Citrate
Other: Magnesium Oxide

First Posted Date: 2016-02-24

Last Posted Date: 2019-09-06

Lead Sponsor: Ottawa Hospital Research Institute

Target Recruit Count: 15

Registration Number: NCT02690012

Locations: 🇨🇦
The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada

Taima TB: 3HP Study

Phase 4

Completed

Conditions: Tuberculosis

Interventions: Drug: 3HP

First Posted Date: 2016-02-23

Last Posted Date: 2020-03-24

Lead Sponsor: Ottawa Hospital Research Institute

Target Recruit Count: 182

Registration Number: NCT02689089

Locations: 🇨🇦
The Ottawa Hospital - General Campus, Ottawa, Ontario, Canada

REaCT-vascular Access Her2 Negative Vascular Access Strategies for (Neo) Adjuvant Breast Cancer Treatment Without Trastuzumab

Not Applicable

Completed

Conditions: Breast Cancer
Cancer

Interventions: Device: venous access PORT or PICC

First Posted Date: 2016-02-23

Last Posted Date: 2019-09-06

Lead Sponsor: Ottawa Hospital Research Institute

Target Recruit Count: 150

Registration Number: NCT02688998

Locations: 🇨🇦
The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada

Multicentre Study to Determine the Feasibility of Using an Integrated Consent Model to Compare Three Standard of Care Regimens for The Treatment of Triple-Negative Breast Cancer in the Neoadjuvant/Adjuvant Setting (REaCT-TNBC)

Phase 4

Completed

Conditions: Breast Cancer

Interventions: Drug: Dose dense AC-P
Drug: Dose dense AC
Drug: FEC-D

First Posted Date: 2016-02-23

Last Posted Date: 2019-03-28

Lead Sponsor: Ottawa Hospital Research Institute

Target Recruit Count: 2

Registration Number: NCT02688803

Locations: 🇨🇦
The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada

StAtins for Venous Event Reduction in Patients With Venous Thromboembolism Pilot Study

Phase 2

Conditions: Venous Thromboembolism

Interventions: Drug: Rosuvastatin

First Posted Date: 2016-02-10

Last Posted Date: 2020-02-27

Lead Sponsor: Ottawa Hospital Research Institute

Target Recruit Count: 312

Registration Number: NCT02679664

Locations: 🇳🇴
Østfold Hospital Trust, Grålum, Norway
🇨🇦
Hamilton Health Sciences Corporation, Hamilton, Ontario, Canada
🇨🇦
Nova Scotia Health Authority, Halifax, Nova Scotia, Canada

and more 3 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy